PL1981506T6 - Długoterminowe leczenie zakażenia HIV z zastosowaniem TCM278 - Google Patents

Długoterminowe leczenie zakażenia HIV z zastosowaniem TCM278

Info

Publication number
PL1981506T6
PL1981506T6 PL07712053T PL07712053T PL1981506T6 PL 1981506 T6 PL1981506 T6 PL 1981506T6 PL 07712053 T PL07712053 T PL 07712053T PL 07712053 T PL07712053 T PL 07712053T PL 1981506 T6 PL1981506 T6 PL 1981506T6
Authority
PL
Poland
Prior art keywords
tcm278
hiv
infection
long term
term treatment
Prior art date
Application number
PL07712053T
Other languages
English (en)
Other versions
PL1981506T3 (pl
Inventor
Lieven Elvire Colette Baert
Guenter Kraus
Gerben Albert Eleutherius Van 't Klooster
Original Assignee
Janssen Sciences Ireland Uc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36446113&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL1981506(T6) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Sciences Ireland Uc filed Critical Janssen Sciences Ireland Uc
Publication of PL1981506T3 publication Critical patent/PL1981506T3/pl
Publication of PL1981506T6 publication Critical patent/PL1981506T6/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL07712053T 2006-01-20 2007-01-19 Długoterminowe leczenie zakażenia HIV z zastosowaniem TCM278 PL1981506T6 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06100677 2006-01-20
EP07712053.3A EP1981506B3 (en) 2006-01-20 2007-01-19 Long term treatment of hiv- infection with tcm278
PCT/EP2007/050516 WO2007082922A2 (en) 2006-01-20 2007-01-19 Long term treatment of hiv- infection with tcm278

Publications (2)

Publication Number Publication Date
PL1981506T3 PL1981506T3 (pl) 2013-08-30
PL1981506T6 true PL1981506T6 (pl) 2021-07-12

Family

ID=36446113

Family Applications (1)

Application Number Title Priority Date Filing Date
PL07712053T PL1981506T6 (pl) 2006-01-20 2007-01-19 Długoterminowe leczenie zakażenia HIV z zastosowaniem TCM278

Country Status (27)

Country Link
US (4) US10953009B2 (pl)
EP (1) EP1981506B3 (pl)
JP (2) JP5754005B2 (pl)
KR (2) KR101501475B1 (pl)
CN (2) CN103877091A (pl)
AP (1) AP2936A (pl)
AR (1) AR059097A1 (pl)
AU (1) AU2007206901B2 (pl)
BR (1) BRPI0707179A2 (pl)
CA (1) CA2636436C (pl)
CY (1) CY1114089T1 (pl)
DK (1) DK1981506T6 (pl)
EA (1) EA014914B1 (pl)
ES (1) ES2414982T7 (pl)
HR (1) HRP20130544T4 (pl)
IL (1) IL192132A (pl)
ME (1) ME01617B (pl)
MY (1) MY150717A (pl)
NZ (1) NZ569347A (pl)
PL (1) PL1981506T6 (pl)
PT (1) PT1981506E (pl)
RS (1) RS52821B2 (pl)
SG (1) SG170073A1 (pl)
SI (1) SI1981506T1 (pl)
TW (1) TWI458483B (pl)
UA (1) UA96436C2 (pl)
WO (1) WO2007082922A2 (pl)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY169670A (en) 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
TWI457136B (zh) * 2005-04-04 2014-10-21 Tibotec Pharm Ltd Ｈｉｖ-感染之預防
CA2636436C (en) 2006-01-20 2014-04-01 Tibotec Pharmaceuticals Ltd. Long term treatment of hiv- infection with tmc278
AU2014200819B2 (en) * 2006-06-23 2016-05-26 Janssen Sciences Ireland Uc Aqueous suspensions of TMC278
AU2016219555B2 (en) * 2006-06-23 2017-08-10 Janssen Sciences Ireland Uc Aqueous suspensions of TMC278
PT2040671T (pt) * 2006-06-23 2018-03-14 Janssen Sciences Ireland Uc Suspensões aquosas de tmc278
AR065720A1 (es) 2007-03-14 2009-06-24 Tibotec Pharm Ltd Polvos para reconstitucion que comprenden rilpivirina dispersos en ciertos polimeros. uso. proceso.
CN102711834B (zh) * 2008-12-24 2015-08-26 爱尔兰詹森科学公司 治疗hiv的可植入装置
CN102573815B (zh) * 2009-09-22 2015-09-30 泰博特克药品公司 Hiv感染的治疗和预防
US8784858B2 (en) 2009-12-21 2014-07-22 Janssen R&D Ireland Degradable removable implant for the sustained release of an active compound
UA105556C2 (uk) * 2010-01-27 2014-05-26 Віів Гелскер Компані Комбінація сполук, що містить інгібітори віл інтегрази з іншими терапевтичними агентами
TWI577377B (zh) 2010-09-16 2017-04-11 Ｖｉｉｖ醫療保健公司 醫藥組合物
US9266824B2 (en) 2014-01-13 2016-02-23 Warsaw Orthopedic, Inc. Methods and compositions for making an amino acid triisocyanate
CN108289844B (zh) * 2015-11-16 2021-09-14 赢创运营有限公司 包含非核苷逆转录酶抑制剂和聚(丙交酯-共-乙交酯)的注射溶液
US20190163877A1 (en) * 2017-11-27 2019-05-30 International Business Machines Corporation Decision support for effective long-term drug therapy
WO2022079739A1 (en) 2020-10-14 2022-04-21 Cipla Limited Fixed dose compositions of cabotegravir and rilpivirine

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
JPH06316524A (ja) 1992-09-11 1994-11-15 Naoyuki Inoue 抗エイズウイルス剤
US6045829A (en) 1997-02-13 2000-04-04 Elan Pharma International Limited Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers
UA72189C2 (uk) 1997-11-17 2005-02-15 Янссен Фармацевтика Н.В. Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот
US6258932B1 (en) 1999-08-09 2001-07-10 Tripep Ab Peptides that block viral infectivity and methods of use thereof
JP2003509453A (ja) 1999-09-21 2003-03-11 アールティーピー・ファーマ・インコーポレーテッド 生物学的に活性な物質の、表面改質された粒状組成物
BR0109602A (pt) 2000-03-30 2004-06-29 Bristol Myers Squibb Co Glóbulos de liberação controlada contendo estavudina
US20040115268A1 (en) 2000-04-26 2004-06-17 Control Delivery Systems, Inc. Systemic delivery of antiviral agents
MY169670A (en) 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
JO3429B1 (ar) 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
US7638522B2 (en) 2001-08-13 2009-12-29 Janssen Pharmaceutica N.V. Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino] benzonitrile
US20030166509A1 (en) 2001-11-20 2003-09-04 Advanced Inhalation Research, Inc. Compositions for sustained action product delivery and methods of use thereof
US6568805B1 (en) * 2001-11-26 2003-05-27 Dan L. Dietz Trust Magnetic buckle for eyeglasses
US7094413B2 (en) * 2002-01-24 2006-08-22 Sangstat Medical Corporation Combined therapy for treatment of HIV infection
AU2003291457A1 (en) 2002-11-08 2004-06-03 Glaxo Group Limited Pharmaceutical antiviral compositions
US7204980B2 (en) 2002-11-18 2007-04-17 Phoenix Pharmacologics, Inc. Methods for inhibiting viral replication in vivo
PL227577B1 (pl) 2003-02-07 2017-12-29 Janssen Pharmaceutica Nv Zastosowanie pochodnych pirymidyny do wytwarzania leku do zapobiegania zakażeniu wirusem HIV oraz kompozycja farmaceutyczna
NZ541883A (en) 2003-02-21 2008-12-24 Tripep Ab Glycinamide derivative for inhibiting HIV replication
DK1632232T6 (da) 2004-09-02 2022-04-19 Janssen Pharmaceutica Nv Salt af 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]¬amino]¬benzonitril
WO2006024668A1 (en) * 2004-09-02 2006-03-09 Janssen Pharmaceutica N.V. Hydrochloride of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl] amino]benzonitrile
AU2005307797B2 (en) 2004-11-16 2011-06-02 Alkermes Pharma Ireland Limited Injectable nanoparticulate olanzapine formulations
TWI457136B (zh) 2005-04-04 2014-10-21 Tibotec Pharm Ltd Ｈｉｖ-感染之預防
CA2636436C (en) 2006-01-20 2014-04-01 Tibotec Pharmaceuticals Ltd. Long term treatment of hiv- infection with tmc278
PT2040671T (pt) 2006-06-23 2018-03-14 Janssen Sciences Ireland Uc Suspensões aquosas de tmc278
US8426434B2 (en) 2007-07-12 2013-04-23 Tibotec Pharmaceuticals Ltd. Crystalline form of 4-[[4-[[4-(2-Cyanoethenyl)-2,6-dimethylphenyl]-amino]-2-pyrimidinyl]amino]benzonitrile

Also Published As

Publication number Publication date
UA96436C2 (ru) 2011-11-10
KR20140141699A (ko) 2014-12-10
JP5754005B2 (ja) 2015-07-22
HK1125828A1 (en) 2009-08-21
WO2007082922A8 (en) 2008-01-03
AU2007206901A1 (en) 2007-07-26
NZ569347A (en) 2011-07-29
US20110275654A1 (en) 2011-11-10
USRE50189E1 (en) 2024-10-29
RS52821B (sr) 2013-10-31
RS52821B2 (sr) 2021-07-30
US20210177843A1 (en) 2021-06-17
ES2414982T3 (es) 2013-07-23
AU2007206901B2 (en) 2013-01-31
JP5836983B2 (ja) 2015-12-24
PL1981506T3 (pl) 2013-08-30
ES2414982T7 (es) 2021-11-05
AP2008004535A0 (en) 2008-08-31
TWI458483B (zh) 2014-11-01
IL192132A (en) 2014-05-28
DK1981506T6 (da) 2021-06-14
EA200870183A1 (ru) 2009-12-30
EP1981506A2 (en) 2008-10-22
DK1981506T3 (da) 2013-06-24
AR059097A1 (es) 2008-03-12
EP1981506B3 (en) 2021-06-09
PT1981506E (pt) 2013-06-25
CA2636436C (en) 2014-04-01
CY1114089T1 (el) 2016-07-27
EP1981506B1 (en) 2013-03-27
US10953009B2 (en) 2021-03-23
AP2936A (en) 2014-07-31
IL192132A0 (en) 2009-08-03
WO2007082922A3 (en) 2007-09-20
SI1981506T1 (sl) 2013-08-30
US20240226099A1 (en) 2024-07-11
KR20080085194A (ko) 2008-09-23
CN101370504A (zh) 2009-02-18
EA014914B1 (ru) 2011-02-28
KR101501475B1 (ko) 2015-03-19
BRPI0707179A2 (pt) 2011-04-26
HRP20130544T1 (en) 2013-07-31
HRP20130544T4 (hr) 2021-08-20
JP2013100338A (ja) 2013-05-23
CA2636436A1 (en) 2007-07-26
TW200806295A (en) 2008-02-01
JP2009526758A (ja) 2009-07-23
WO2007082922A2 (en) 2007-07-26
MY150717A (en) 2014-02-28
ME01617B (me) 2014-09-20
SG170073A1 (en) 2011-04-29
CN103877091A (zh) 2014-06-25
KR101562943B1 (ko) 2015-10-23

Similar Documents

Publication Publication Date Title
IL192132A0 (en) Long term treatment of hiv-infection with tcm278
HUS1800011I1 (hu) Kombinációs terápia szubsztituált oxazolidinonokkal
GB0610867D0 (en) Treatment of pain
IL193748A0 (en) Treatment of pain
GB0624874D0 (en) Treatment
GB0702931D0 (en) Skin application
GB0909297D0 (en) Composition for the treatment of skin conditions
ZA200901452B (en) Treatment of vertigo with acetyl-L-leucine
GB0600692D0 (en) Well treatment
ZA200806505B (en) Treatment of HIV
GB0723100D0 (en) Treatment of HFnEF
GB0610868D0 (en) Treatment of pain
GB0607952D0 (en) Novel treatment
GB0604460D0 (en) Treatment
GB0714500D0 (en) composition and treatment
GB0616450D0 (en) Treatment of pain
GB0602857D0 (en) The treatment of sialorrhoea
GB0623740D0 (en) Treatment of disease
GB0602855D0 (en) The Treatment Of Sialorrhoea
GB0602858D0 (en) The treatment of sialorrhoea
GB0625602D0 (en) Treatment of sialorrhoea
GB0601091D0 (en) The Treatment Of Ocular Conditions
GB0605781D0 (en) Treatment
GB0610431D0 (en) Treatment
GB0609789D0 (en) Treatment of inflammation